Drug intelligence / Profile preview

3'-fucosyllactose

Development stage
Unknown
Lead developer
Glycom
Modality
Microbiome-Derived Products → Microbiome Therapeutics
Administration
Oral
01

Overview

**3'-Fucosyllactose (3'-FL)** is a trisaccharide human milk oligosaccharide (HMO) naturally abundant in breast milk, second only to 2'-fucosyllactose after early lactation, consisting of lactose with an α1-3 linked fucose on the glucose residue. It functions primarily as a prebiotic, selectively promoting growth of beneficial gut bacteria like *Bifidobacteria* and *Lactobacillus*, leading to increased production of short-chain fatty acids (SCFAs) that strengthen intestinal barrier integrity, regulate metabolism, and exert anti-inflammatory effects by reducing pro-inflammatory cytokines such as IL-6 and TNF-α. Additional benefits include immunomodulation via cell signaling and microbial adhesion inhibition, antimicrobial activity against pathogens like *E. coli* and *P. aeruginosa*, support for brain development through sialic acid provision and gut-brain axis regulation, and antiviral protection; it is produced via microbial fermentation for use in infant formulas, foods, and supplements, with regulatory approvals confirming safety up to levels mimicking breast milk exposure.

Other names
3-FL3-fucosyllactose

Beyond the preview

Go deeper on 3'-fucosyllactose.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 3'-fucosyllactose.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call